IDEAYA Biosciences, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in South San Francisco, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $219 million and a loss of $114 million (its filed statements).
Product businessPharmaceutical PreparationsSouth San Francisco, CAfilings since 20168 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 5.1 out of ten, present 7.1 out of ten, future 6.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.8 out of ten. 7 filed years; profitable in 0 of 7. 38th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.3 out of ten. CrossAssetData estimate 3.3/10, confidence 35 of 100 (one part). 33rd percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 7.8 out of ten. ROE -11%: lost 11¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar. 78th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 7.0 out of ten. top 30% of 314 in its family; net margin -52%. 70th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.8 out of ten. top 42% of 315 in its family for leadership; chief executive since 2019. 58th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 4.6 out of ten. bottom 46% of 272 in its family for room to expand. 46th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 8.1 out of ten. top 19% of 307 in its family for growth drivers. 81st percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 7.9 out of ten. top 21% of 234 in its family for expectations against reality. 79th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-17 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-04 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form 4, 2026-10-08. Filings on record since 2016. Read from EDGAR 2026-10-12.
Who runs it
Hata, Yujiro S (President and CEO); Bleharski, Joshua (Chief Financial Officer); Ruiz, Briseno Andres (Chief Accounting Officer); Ross, Theodora (Chief Development Officer); Beaupre, Darrin (Chief Medical Officer); Dorman, Stuart (Chief Commercial Officer); White, Michael Anthony (Chief Scientific Officer); Snyder, Douglas B. (SVP, General Counsel); Hampton, Malcolm Garret (director); Mackey, Catherine J (director); and 4 more. 14 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-08.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.